Overview

3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

Status:
Not yet recruiting

Trial end date:
2023-04-05

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.

Phase:

Phase 2

Details

Lead Sponsor:

3D Medicines

Treatments:

Oxycodone